These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

152 related items for PubMed ID: 37464793

  • 61. The efficacy of 99mTc-HYNIC-PSMA SPECT/CT in detecting primary lesions and metastasis in newly diagnosed prostate cancer.
    Wang T, Zhao L, Qiao W, Sun N, Zhao J, Xing Y.
    Front Oncol; 2023; 13():1165694. PubMed ID: 37333816
    [Abstract] [Full Text] [Related]

  • 62. Application of [68Ga]PSMA PET/CT in Diagnosis and Management of Prostate Cancer Patients.
    Dadgar H, Emami F, Norouzbeigi N, Vafaee MS, Jafari E, Gholamrezanezhad A, Assadi M, Ahmadzadehfar H.
    Mol Imaging Biol; 2020 Aug; 22(4):1062-1069. PubMed ID: 31758511
    [Abstract] [Full Text] [Related]

  • 63. Is there a nonnegligible effect of maximum standardized uptake value in the staging and management of prostate cancer with 68Ga-prostate-specific membrane antigen positron emission tomography/computerized tomography imaging? A single-center experience.
    Ekmekcioglu O, Yavuzsan AH, Arican P, Kirecci SL.
    J Cancer Res Ther; 2021 Aug; 17(6):1351-1357. PubMed ID: 34916365
    [Abstract] [Full Text] [Related]

  • 64. 68Ga-PSMA PET/CT for Primary Lymph Node and Distant Metastasis NM Staging of High-Risk Prostate Cancer.
    Klingenberg S, Jochumsen MR, Ulhøi BP, Fredsøe J, Sørensen KD, Borre M, Bouchelouche K.
    J Nucl Med; 2021 Feb; 62(2):214-220. PubMed ID: 32444374
    [Abstract] [Full Text] [Related]

  • 65. 68 Ga-PSMA-PET/CT staging prior to definitive radiation treatment for prostate cancer.
    Hruby G, Eade T, Emmett L, Ho B, Hsiao E, Schembri G, Guo L, Kwong C, Hunter J, Byrne K, Kneebone A.
    Asia Pac J Clin Oncol; 2018 Aug; 14(4):343-346. PubMed ID: 29663686
    [Abstract] [Full Text] [Related]

  • 66. Diagnostic Performance and Clinical Impact of 68Ga-PSMA-11 PET/CT Imaging in Early Relapsed Prostate Cancer After Radical Therapy: A Prospective Multicenter Study (IAEA-PSMA Study).
    Cerci JJ, Fanti S, Lobato EE, Kunikowska J, Alonso O, Medina S, Novruzov F, Lengana T, Granados C, Kumar R, Rangarajan V, Al-Ibraheem A, Hourani M, Ali NS, Ahmad A, Keidar Z, Küçük O, Elboga U, Bogoni M, Paez D.
    J Nucl Med; 2022 Feb; 63(2):240-247. PubMed ID: 34215674
    [Abstract] [Full Text] [Related]

  • 67. A Review on the Current State and Future Perspectives of [99mTc]Tc-Housed PSMA-i in Prostate Cancer.
    Brunello S, Salvarese N, Carpanese D, Gobbi C, Melendez-Alafort L, Bolzati C.
    Molecules; 2022 Apr 19; 27(9):. PubMed ID: 35565970
    [Abstract] [Full Text] [Related]

  • 68. 68Ga-PSMA-11 PET/CT in Newly Diagnosed Prostate Adenocarcinoma.
    Ergül N, Yilmaz Güneş B, Yücetaş U, Toktaş MG, Çermik TF.
    Clin Nucl Med; 2018 Dec 19; 43(12):e422-e427. PubMed ID: 30273204
    [Abstract] [Full Text] [Related]

  • 69. Head-to-head comparisons of [68Ga]Ga-PSMA-11 PET/CT, multiparametric MRI, and prostate-specific antigen for the evaluation of therapeutic responses to neoadjuvant chemohormonal therapy in high-risk non-metastatic prostate cancer patients: a prospective study.
    Ke ZB, Chen SM, Chen JY, Chen SH, You Q, Sun JB, Xue YT, Sun XL, Wu XH, Zheng QS, Wei Y, Xue XY, Xu N.
    Eur J Nucl Med Mol Imaging; 2023 Mar 19; 50(4):1240-1251. PubMed ID: 36416906
    [Abstract] [Full Text] [Related]

  • 70. Planar 99m Tc-PSMA Imaging of Prostate Cancer in a Low-Resource Setting: A Series Report.
    Orunmuyi AT, Oladeji AA, Azodoh EU, Omisanjo OA, Olapade-Olaopa EO.
    World J Nucl Med; 2022 Jun 19; 21(2):142-147. PubMed ID: 35865161
    [Abstract] [Full Text] [Related]

  • 71. Evaluation of Radiation dosimetry of 99mTc-HYNIC-PSMA and imaging in prostate cancer.
    Zhang J, Zhang J, Xu X, Lu L, Hu S, Liu C, Cheng J, Song S, Zhang Y, Shi LQ.
    Sci Rep; 2020 Mar 06; 10(1):4179. PubMed ID: 32144340
    [Abstract] [Full Text] [Related]

  • 72. The Diagnostic Value of PSMA PET/CT in Men with Newly Diagnosed Unfavorable Intermediate-Risk Prostate Cancer.
    Hagens MJ, Luining WI, Jager A, Donswijk ML, Cheung Z, Wondergem M, Oprea-Lager DE, Vis AN, van Leeuwen PJ, van der Poel HG.
    J Nucl Med; 2023 Aug 06; 64(8):1238-1243. PubMed ID: 37385673
    [Abstract] [Full Text] [Related]

  • 73. Utility of Ga68 prostate-specific membrane antigen positron-emission tomography for pre-operative staging of high-risk prostate cancer in a prospective cohort.
    Tarr GP, Kashyap P, Dixit DD, Willams AK, Koya MP, Lim R.
    J Med Imaging Radiat Oncol; 2020 Feb 06; 64(1):78-86. PubMed ID: 31885207
    [Abstract] [Full Text] [Related]

  • 74. Use of gallium-68 prostate-specific membrane antigen positron-emission tomography for detecting lymph node metastases in primary and recurrent prostate cancer and location of recurrence after radical prostatectomy: an overview of the current literature.
    Luiting HB, van Leeuwen PJ, Busstra MB, Brabander T, van der Poel HG, Donswijk ML, Vis AN, Emmett L, Stricker PD, Roobol MJ.
    BJU Int; 2020 Feb 06; 125(2):206-214. PubMed ID: 31680398
    [Abstract] [Full Text] [Related]

  • 75. Higher scrotal uptake ratio of (99m)Tc-MDP on bone scans in newly diagnosed prostate cancer: a reliable indicator of pelvic node metastasis.
    Zaman MU, Fatima N, Sajjad Z, Hashmi I, Khan K.
    Ann Nucl Med; 2012 Oct 06; 26(8):676-80. PubMed ID: 22777858
    [Abstract] [Full Text] [Related]

  • 76. Baseline PSMA-PET/CT as a predictor of PSA persistence following radical prostatectomy in high-risk nonmetastatic prostate cancer patients receiving neoadjuvant therapy.
    Du X, Dong Y, Liu J, Su Y, Zhu Y, Pan J, Dong B, Chen R, Liu J, Tong Z, Pienta KJ, Rowe SP, Dong L, Xue W.
    Prostate; 2023 Aug 06; 83(11):1112-1120. PubMed ID: 37165552
    [Abstract] [Full Text] [Related]

  • 77. 68Ga-PSMA-11 PET/CT in primary staging of prostate cancer: PSA and Gleason score predict the intensity of tracer accumulation in the primary tumour.
    Uprimny C, Kroiss AS, Decristoforo C, Fritz J, von Guggenberg E, Kendler D, Scarpa L, di Santo G, Roig LG, Maffey-Steffan J, Horninger W, Virgolini IJ.
    Eur J Nucl Med Mol Imaging; 2017 Jun 06; 44(6):941-949. PubMed ID: 28138747
    [Abstract] [Full Text] [Related]

  • 78. Diagnostic Accuracy of 64Copper Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography for Primary Lymph Node Staging of Intermediate- to High-risk Prostate Cancer: Our Preliminary Experience.
    Cantiello F, Gangemi V, Cascini GL, Calabria F, Moschini M, Ferro M, Musi G, Butticè S, Salonia A, Briganti A, Damiano R.
    Urology; 2017 Aug 06; 106():139-145. PubMed ID: 28438628
    [Abstract] [Full Text] [Related]

  • 79. The role of PSMA PET/CT imaging in restaging of prostate cancer patients with low prostate-specific antigen levels.
    Kabasakal L, Demirci E, Nematyazar J, Akyel R, Razavi B, Ocak M, Aygun A, Obek C, Kural AR.
    Nucl Med Commun; 2017 Feb 06; 38(2):149-155. PubMed ID: 27893589
    [Abstract] [Full Text] [Related]

  • 80. Comparison of 68Ga-PSMA PET/CT and multiparametric MRI for staging of high-risk prostate cancer68Ga-PSMA PET and MRI in prostate cancer.
    Tulsyan S, Das CJ, Tripathi M, Seth A, Kumar R, Bal C.
    Nucl Med Commun; 2017 Dec 06; 38(12):1094-1102. PubMed ID: 28957842
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.